Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene mutated in a high percentage of hereditary breast and ovarian cancers. The multifunctional BRCA1 protein acts on cell cycle control, exerting several highly specialized DNA repair processes through diverse domains. Gene regulation through its C-terminal domain (BRCT) is indispensable for BRCA1-mediated tumor suppression, suggesting the possibility that the BRCT domain interacts with co-regulator complexes. Using a biochemical approach with HeLa S3 nuclear extracts, we isolated BRCT-associated complexes and identified one of the purified components as TRAP220. We then performed interaction studies in vivo (coimmunoprecipitation) and in vitro (glutathione S-transferase pull-down assays) and showed that BRCT directly interacted with TRAP220. This in vitro interaction was completely abolished by BRCT point mutations typical of those found in patients with BRCA1 that lack transactivation function. BRCA1 transactivation function was dependent on TRAP220 expression level in a transient expression assay. Moreover, a cell survival assay showed that antisense TRAP220 expression to disrupt endogenous TRAP220 expression significantly reduced the survival rate potentiated by BRCA1 after DNA damage. These results suggested that a TRAP220 complex play an important role as putative co-activator complexes in BRCA1-mediated tumor suppression.
Breast cancer susceptibility gene 1 (BRCA1) is a tumor suppressor gene mutated in a high percentage of hereditary breast and ovarian cancers. The multifunctional BRCA1 protein acts on cell cycle control, exerting several highly specialized DNA repair processes through diverse domains. Gene regulation through its C-terminal domain (BRCT) is indispensable for BRCA1-mediated tumor suppression, suggesting the possibility that the BRCT domain interacts with co-regulator complexes. Using a biochemical approach with HeLa S3 nuclear extracts, we isolated BRCT-associated complexes and identified one of the purified components as TRAP220. We then performed interaction studies in vivo (coimmunoprecipitation) and in vitro (glutathione S-transferase pull-down assays) and showed that BRCT directly interacted with TRAP220. This in vitro interaction was completely abolished by BRCT point mutations typical of those found in patients with BRCA1 that lack transactivation function. BRCA1 transactivation function was dependent on TRAP220 expression level in a transient expression assay. Moreover, a cell survival assay showed that antisense TRAP220 expression to disrupt endogenous TRAP220 expression significantly reduced the survival rate potentiated by BRCA1 after DNA damage. These results suggested that a TRAP220 complex play an important role as putative co-activator complexes in BRCA1-mediated tumor suppression. Keywords: BRCA1; TRAP220; breast cancer Germ-line mutation of BRCA1 is well known to predispose women to early onset of breast and ovarian cancer (Venkitaraman, 2002) . The BRCA1 gene encodes a relatively large protein of 1863 amino acids, and apart from an N-terminal zinc-binding RING domain and two C-terminal tandem copies of a BRCT motif, displays little similarity to other known proteins Miki et al., 1994) . The C-terminal BRCT domain has been shown to be involved in doublestranded DNA repair and homologous recombination (Callebaut and Mornon, 1997; Moynahan et al., 1999; Scully et al., 1999; Zhong et al., 1999) . However, the major function of BRCT is thought to be as a gene regulator, mediating BRCA1 function as a tumor suppressor. This hypothesis is based on several lines of evidence, including that the autonomous transactivation function of BRCA1 was preserved in a recombinant protein consisting of the BRCT domain fused to a GAL4 DNA-binding domain (Miyake et al., 2000) . In addition, missense and point mutations in the BRCT domain derived from patients with inherited breast cancer result in the loss of transcriptional activity, and BRCA1 can also act as a negative regulator on some gene promoters (Chapman and Verma, 1996; Monteiro et al., 1996; Zheng et al., 2001; Kawai et al., 2002) . Reflecting the complex nature of BRCT transactivation function, this domain has already been shown to physically interact with a number of transcription factors and co-regulators (presumably in complexes), and also associate with chromatin remodeling complexes (Anderson et al., 1998; Yu et al., 1998; Zhang et al., 1998; Yarden and Brody, 1999; Bochar et al., 2000) . Moreover, transcriptional squelching between BRCA1 and estrogen receptor (ER) has recently been reported (Fan et al., 1999; Zheng et al., 2001) . As ER is a member of the nuclear receptor (NR) gene superfamily and acts as a ligand-induced transcription factor (Mangelsdorf et al., 1995; Watanabe et al., 2001; Yanagisawa et al., 2002) , limited cellular amounts of a common co-activator complex for both BRCA1 and ER could explain the transcriptional squelching phenomenon.
To better understand the BRCT transactivation function, we screened for putative transcription coactivator complexes that directly interacted with the BRCT domain using a biochemical approach. We established an affinity column whereby the BRCT domain (amino acids 1528-1863) was immobilized as a glutathione S-transferase (GST)-fusion protein. Fractions of HeLa S3 nuclear extract, presumably containing multiprotein complexes, were applied to the affinity column (Yanagisawa et al., 2002; Kitagawa et al., 2003) , and several of the transcription co-regulators subsequently verified in the BRCT-interacting complexes by Western blotting (Figure 1b , lower panel). Western blotting of the BRCT-interacting complexes identified TRAP220 and TRAP100 (Figure 1b ), which were confirmed as factors that associate with BRCT by time-of-flight mass spectrometry (TOF-MS). TRAP220 contains two LXXLL motifs, which are consensus interacting motifs and part of the core activation domain in NR ligand-binding domains Rachez et al., 1999) . Thus, TRAP220 is thought to act as a major and direct interactant with ER (Yanagisawa et al., 2002) , as well as with other NRs, as part of the common TRAP/DRIP co-activator complex (Rachez et al., 1999) . It is therefore possible that the functional role of TRAP220 in the TRAP/ DRIP complex may account for the reported transcriptional squelching between ER and BRCA1. Indeed, several other BRCT-associated proteins we identified were also TRAP/DRIP complex components, such as TRAP220, TRAP240, DRIP130, and TRAP80 . BACH1 (Cantor et al., 2001 ) and p300 (Pao et al., 2000) were also detected by TOF-MAS and Western blotting (Figure 1b) , respectively, and have been previously shown to interact with BRCT, which confirmed the efficacy of our purification method.
To address the functional importance of the BRCT-TRAP220 interaction, a BRCT point-mutant, derived from a breast cancer patient and deficient in transcriptional activity, was used to isolate interacting complexes. As clearly shown in Figure 3b , the GST-fused BRCT point-mutant (M1775R) protein lacked the ability to retain TRAP220 on the column. This indicated that TRAP220 may function as a co-activator in the BRCA1 complex. To determine whether full-length BRCA1 protein interacted with TRAP220 in human cells, we expressed full-length BRCA1 (FLAG epitope-tagged) and/or TRAP220 (His/Myc epitope-tagged) in 293T cells. Significant expression of the tagged proteins was confirmed by Western blotting. After immunoprecipitation with anti-FLAG M2 to obtain full-length BRCA1, the immunoprecipitants were blotted with anti-Myc to identify TRAP220-containing complexes (Figure 2a ). Both TRAP220 and BRCA1 were detected in cell lysate immunoprecipitates (Figure 2a) , which supported the hypothesis that BRCA1 physically associates with TRAP220 in living cells. This hypothesis was further confirmed by in vivo association between endogenous BRCA1 and TRAP220 in MCF-7 cells expressing both proteins (Figure 2b ). No such association was observed when the BRCA1 point-mutant (M1775R) was used instead of wild-type BRCA1 in the immunoprecipitation experiment (Figure 2a) , as expected from the results of the column purification experiments.
To map the region of TRAP220 that interacted with BRCT, a GST pull-down assay was performed using TRAP220 deletion mutants (Figure 3a) . FLAG-tagged TRAP220 fragments, abbreviated TR1, TR2, TR3, TR4 and TR5 (as described in Figure 3a) , were in vitro translated in the presence of [
35 S]methionine and incubated with GST-fused BRCT protein-bound resin. Only TR1 was trapped, which suggested that only the TR1 region interacted with BRCT. Interestingly, the Figure 1 Affinity purification of BRCT-containing complexes (a) Purification scheme. HeLa S3 nuclear extract was fractionated using a phosphocellulose (P11) column and a GST-BRCT (amino acids 1528-1863) affinity column. The 1 M KCl P11 eluate was concentrated onto the GST-BRCT affinity column at 41C for 10-12 h. Bound proteins were washed extensively with buffer, and subsequently eluted by buffer containing 20 mM reduced glutathione. As a negative control, purification from P11 eluates was performed using another affinity column (immobilized GST-BRCT M1775R). (b) Purified fractions were boiled, separated by electrophoresis and analysed by SDS-PAGE followed by silver staining or Western blot analysis using antibody, as shown on the right of the figure. Molecular weight standards are shown to the left of the figure. The asterisk denotes the molecular bait (GST-BRCT, GST-BRCT M1775R) after elution. Arrows show proteins identified by mass spectrometry (Yanagisawa et al., 2002) BRCA1 function and TRAP220 O Wada et al BRCT column did not retain either TR2 or TR3, which contain LXXLL motifs thought to interact with liganded NRs. Reflecting the associations between TRAP220 and wild-type or point-mutant BRCA1 as observed in our in vivo experiments, the point-mutations A1708E, P1749R, and M1775R that exhibit no BRCA1 transactivation function caused the loss of TRAP220 interaction in vitro (Figure 3b) .
To examine the co-activator activity of TRAP220 toward BRCT transactivation function, a transient transfection assay was performed using a luciferase reporter plasmid driven by the adenovirus major late promoter (AdMLP) containing GAL4DBD-binding sites. A BRCT-GAL4DBD-fusion protein (GAL-BRCT) alone potently stimulated transcription (Figure 4b ). TRAP220 expression in human 293T cells led to an approximately twofold increase in luciferase activity compared to GAL-BRCT alone, while such coactivation was not detected in a TRAP220 deletion mutant lacking the BRCT interacting TR1 region (amino acids 1-326, see Figure 3a ) (Figure 4b ). This enhancement of transactivation by TRAP220 was not observed when either GAL4 DNA-binding domain alone or GAL-BRCT mutants (A1708E, P1749R, or M1775R) were used, as expected from the in vivo and in vitro TRAP220 experiments. Consistent with these findings, antisense TRAP220 expression, that disrupted endogenous TRAP220 expression (Figure 4a ), reduced the transcriptional activity of BRCT (Figure 4b ). This again suggested a significant role for TRAP220 in BRCA1 transactivation function.
Finally, we then tested the significance of TRAP220 activity in the DNA damage response mediated by BRCA1. BRCA1 was transfected into HCC1937 cells (a Figure 2 In vivo association between TRAP220 and BRCA1. (a) Formation of BRCA1 and TRAP220 complexes in 293T cells was analysed by co-immunoprecipitation (IP) using the anti-FLAG monoclonal M2 antibody (Sigma Aldrich) followed by immunoblotting (IB) using anti-Myc. 293T cells were transiently transfected with combinations of expression vectors as indicated. The expression of proteins in transfected cell extracts was determined by Western blot analysis using FLAG or Myc tags. (b) Detection of endogenous BRCA1-TRAP220 interaction by Western blotting. MCF-7 nuclear extracts were applied for immunoprecipitation with 5 mg of anti-BRCA1 (MS-BRC14-UP50, GeneTex, Inc.) and IgG, respectively. Then bound proteins in 30 ml of protein G sepharoset 4 Fast Flow (Amersham Biosciences, NJ, USA) were detected by Western blotting. The 10% amount of the tested nuclear extracts is shown as positive control as input Figure 3 In vitro association between TRAP220 and BRCT, and mapping of the BRCT-interacting region of TRAP220. (a) Mapping of the BRCT-interacting region of TRAP220 using GST-BRCT and TRAP220 fragments. Bacterially expressed GST-fusion proteins immobilized on beads were used in in vitro pull-down assays. A schematic diagram of the structure of TRAP220 is shown. TRAP220 'TR1' (amino acids 1-326), 'TR2' (326-620), 'TR3' (620-969), 'TR4' (969-1298), and 'TR5' (1298-1582) were in vitro translated in the presence of [ 35 S]methionine (Amersham Pharmacia Biotech) using a TNT coupled in vitro translation system (Promega). Each labelled TRAP220 fragment was then incubated with either GST alone or GST-BRCT. The mixtures were washed and subjected to SDS-PAGE and analysed. Polyacrylamide gels were stained briefly with Coomassie Brilliant Blue to verify the loading of equal amounts of fusion proteins prior to drying and autoradiography (Ohtake et al., 2003) . (b) In vitro association of TRAP220 with BRCT or BRCT point mutants that lack transcriptional activity were performed by incubating GST, GST-BRCT, GST-BRCT A1708E, P1749R, or M1775R with in vitro translated TRAP220
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O Wada et al mutated BRCA1 cell line) that are hypersensitive to DNA damaging agents such as methylmethane sulfonate (MMS). By counting the number of surviving HCC1937 cells, we observed a protective effect of BRCA1 expression in response to DNA damage. Antisense TRAP220 expression resulted in specific deterioration in the DNA damage response potentiated by BRCA1 (Figure 4c) , which verified the importance of TRAP220 in BRCA1 function. BRCA1 is a multifunctional protein that acts as a tumor suppressor controlling gene expression, as well as a sequence-specific regulator and a co-regulator controlling DNA damage (Venkitaraman, 2002) . Therefore, it can be speculated that BRCA1 acts as a platform protein that associates with a number of factors, regulators, and complexes to accomplish the diverse functions attributed to BRCA1. Indeed, discrete classes of factors and complexes involved in gene regulation and DNA repair associated with BRCA1 have been identified, and indirect associations with further related factors and complexes are supposed. Nevertheless, clear relationships between BRCA1 gene mutation and consequent malfunctions of the identified factors and complexes remain to be established. To this end, we searched for co-activator complexes that recognized the BRCT domain, as mutations in this domain modulate BRCA1 transactivation function and are highly related with breast and ovarian cancer incidence (Humphrey et al., 1997; Greenman et al., 1998) . Also, a previous report found that BRCA1 competed with ER in terms of transcriptional control via the BRCT domain, which suggested the possibility of common co-activator complexes between ER and BRCA1, presumably including the TRAP/DRIP complex already identified as an ER co-activator complex Rachez et al., 1999; Yanagisawa et al., 2002) .
In this study based on biochemical approaches (Yanagisawa et al., 2002; Kitagawa et al., 2003) , we showed that a TRAP220-containing complex associated with wild-type BRCT through physical interaction with TRAP220. As TRAP220 binding of BRCA1 was abrogated in vivo and in vitro when clinically relevant BRCA1 mutants that lacked transactivation function (Chapman and Verma, 1996) were used as bait, the association between BRCT and TRAP220 complexes appears to be critical for normal BRCA1 function. This is supported by the findings that TRAP220 alone potently enhanced BRCA1 transactivation function, and that the disruption of endogenous TRAP220 by antisense TRAP220 led to a clear reduction in BRCA1-mediated DNA damage repair. This last result suggested that TRAP220-containing complexes may also play a role in the DNA damage repair function of BRCA1.
The TRAP/DRIP mediator complex was originally isolated as a co-activator complex for different classes of activators, including NRs, by several independent groups (Fondell et al., 1996; Rachez et al., 1999) . Further study of the isolated complex components Transient transfection assays of GAL-BRCT and FLAG-TRAP220 using a luciferase reporter (Promega) containing the GAL4 DNA-binding site (17M8) showed specific enhancement of transcription. 293T cells were transfected with each luciferase reporter (E1b-Luc and AdMLP-Luc), pM or pM-BRCT, pRL CMV-Luc as a control of transfection efficiency, and either pcDNA3 (Invitrogen) empty expression vector, pcDNA FLAG-TRAP220, pcDNA TRAP220DTR1 or antisense TRAP220. Measurements of luciferase (Promega) activity were performed according to the manufacturer's instructions. Error bars indicate the standard deviation. Each experiment was repeated at least three times in triplicate (Watanabe et al., 2001) . (c) HCC1937 cells were transfected with constructs based on the pcDNA3 plasmid. Cultures were treated with 0.1% MMS for 50 min, and surviving cells were counted after 8 days, as previously described by Zhong et al. (1999) BRCA1 function and TRAP220 O Wada et al revealed that the complexes formed a class of coactivator complexes that shared common major components along with limited numbers of specific factors . Combinations of these specific components generate a number of TRAP/DRIP complex subclasses (Freedman, 1999) . The co-activator function of TRAP/ DRIP complexes in in vitro transcription systems illustrates the direct link of the activator complex to the basal transcription machinery. The 220-kDa component of the complex, referred to as TRAP220/ DRIP230, was identified as a subunit with unique properties in that it directly binds to NRs in a liganddependent manner through a region containing NR recognition motifs (LXXLL, NR box) Rachez et al., 1999) . Given that BRCA1 may compete with ER with respect to gene regulation, and that mutations in the BRCT region lead altered BRCA1-dependent gene regulation and enhanced tumorigenesis in estrogen-dependent cancers (presumably through modulation of ER-mediated estrogen signaling), interaction between TRAP220 and BRCA1 may account for the transcriptional squelching observed between BRCA1 and ER (Fan et al., 1999; Zheng et al., 2001) .
The results of our study showed that TRAP220 bound directly to wild-type BRCA1, but not to BRCA1 mutants. Thus, breast cancer predisposition caused by genetic mutations in the BRCT domain may be due, at least in part, to insufficient interaction with TRAP complexes. In this respect, it is perhaps surprising that gene amplification or overexpression of TRAP220 is observed in some cancer cell lines (Zhu et al., 1999) . Our transient transfection assay showed that TRAP220 enhanced BRCT-mediated transactivation function, such that the TRAP complex clearly served as a coactivator complex in the promoters of BRCA1 target genes. In conclusion, we propose that the failure of binding between BRCT and TRAP220 is a key event in cancer predisposition. Further investigations should be performed to elucidate the molecular mechanisms that underlie the formation BRCA1-TRAP complexes in normal cell growth, thereby revealing its role as a tumor suppressor in estrogen-responsive organs, especially the breast and ovary.
Abbreviations BRCA1, breast cancer susceptibility gene 1; GST, glutathione S-transferase; CMV, cytomegalovirus; AdMLP, adenovirus major late promoter; NR, nuclear receptor.
